
    
      Background. Highly Active AntiRetroviral Therapy including protease inhibitors is associated
      with elevated plasma lipid levels.

      Design. randomized double-blind, multicentric.

      Intervention. Pravastatin versus placebo for 12 weeks.

      Eligibility criteria. Positive for anti-VIH antibodies, stable antiretroviral therapy
      including at least one PI for >= 3 months, plasma HIV-RNA level of < 50 copies/mL for >= 3
      months before randomization, total cholesterol >= 5.5 mmol/L with LDL-cholesterol >= 3.4
      mmol/L on fasting status after three months of standardized dietary advice, written informed
      consent

      Outcomes. HIV RNA at 12 weeks
    
  